ResMed achieved strong second-quarter results for fiscal year 2026, marked by 11% revenue growth and significant margin expansion, driven by innovation in digital health solutions.

• Revenue increased by 11%, with 9% growth on a constant currency basis, reflecting robust demand across product categories.
• Operating margin improved by 310 basis points year-over-year, with GAAP EPS rising by 16%.
• Global devices revenue grew high single-digits, while masks and accessories experienced double-digit growth, aided by strategic market initiatives.
• Successful launch of new fabric masks enhances ResMed's competitive edge in the market.
• Continued strong cash flow and a solid balance sheet position the company well for future growth and shareholder returns.